| Trial ID: | L2977 |
| Source ID: | NCT04830462
|
| Associated Drug: |
Rifampicin 300 Mg Oral Capsule
|
| Title: |
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Latent Tuberculosis|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rifampicin 300 Mg Oral Capsule|DRUG: Isoniazid 300 Mg ORAL TABLET
|
| Outcome Measures: |
Primary: OGTT (oral glucose tolerance test), Reduction in plasma glucose area under the curve during OGTT, Time Frame: 4-6 months (depending on treatment) | Secondary: Changes in insulin production, Insulin/c-peptid, HOMA-B pre and post treatment, Time Frame: 4-6 months (depending on treatment)|Changes in insulin resistance, HOMA-IR pre and post treatment, Time Frame: 4-6 months (depending on treatment)|Changes in low-grade inflammatory markers and in adipokines, A panel of cytokines and adipokines, Time Frame: 4-6 months (depending on treatment)|INF-gamma change, Changes in IFN-γ levels after incubation with saline solution, TB antigen or phytohemagglutinin A Pre, during and post treatment, Time Frame: 4-6 months (depending on treatment)|Changes in body composition, Body composition pre and post treatment measured with DEXA-scanning and/or bioimpedance, Time Frame: 4-6 months (depending on treatment)
|
| Sponsor/Collaborators: |
Sponsor: Herlev and Gentofte Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2021-04-15
|
| Completion Date: |
2023-05-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-05-16
|
| Locations: |
Herlev-Gentofte Hospital, Copenhagen, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT04830462
|
